Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price: 1,678.20
Bid: 1,677.80
Ask: 1,678.40
Change: 13.60 (0.82%)
Spread: 0.60 (0.04%)
Open: 1,669.40
High: 1,679.60
Low: 1,667.20
Yest. Close: 1,664.60
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

GlaxoSmithKline's Zejula application accepted by US Food and drug administration

Mon, 24th Jun 2019 13:18

(Sharecast News) - GlaxoSmithKline (GSK) confirmed on Monday Tesaro, its oncology-focused business, submitted a supplemental new drug application to the US Food & Drug Administration for its Zejula cancer treatment. The application, supports a potential new indication for the treatment of certain advanced ovarian, fallopian tube, or primary peritoneal cancer patients, was granted priority review and has an action date of October 24. The London-listed company said the treatment has already faced a large multicenter, open-label, single-arm, phase 2 study that evaluated its safety and activity in adult patients who were treated with three or more previous chemotherapy regimens. Mary Lynne Hedley, president and chief operating officer of Tesaro, said: "The results of the Quadra study demonstrate that Zejula is active as a late-line treatment for patients beyond those with BRCA mutations. With this study, we continue to advance our mission to provide more patients with ovarian cancer an opportunity to benefit from treatment with Zejula." Ovarian cancer is the fifth most frequent cause of cancer death among women, with 22,000 women diagnosed each year in the United States, and more than 65,000 annually diagnosed in Europe. Hal Barron, chief scientific officer and president of R&D at GSK, said: "We know Zejula plays an important role in helping women with ovarian cancer whose disease has progressed despite initial therapy. Our hope is that over time, our ongoing clinical trials will demonstrate that this medicine can benefit even more patients." GlaxoSmithKline's shares were up 1.12% at 1,594.00p at 1613 BST.

More News

WINNERS & LOSERS SUMMARY: Plus500 Up On Share Buyback, New Customers

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Tuesday.----------FTSE 100 - WINNERS----------TUI, up

13 Aug 19 10:09

LONDON MARKET OPEN: TUI And Plus500 Both Rise Despite Profit Falls

(Alliance News) - Stock prices in London opened lower on Tuesday as concerns about the US-China trade war, protests in Hong Kong, and fears of a global economic slowdown continue to sap sentiment.

13 Aug 19 08:43

Glaxo US Pharma Head To Leave Role, Poaches Merck KGaA Oncology Head

(Alliance News) - GlaxoSmithKline PLC said on Monday that the head of its US pharmaceuticals division Jack Bailey will step down at the end of the year and will be replaced by Merck KGaA's the

12 Aug 19 17:00

MidaTech Pharma Appoints Frederic Duchesne As Non-Executive Director

(Alliance News) - Midatech Pharma PLC said Wednesday that Frederic Duchesne had been appointed as a non-executive director, effective immediately.Duchesne was chief executive of the of May.

31 Jul 19 15:54

GlaxoSmithKline Notes Positive Tango And Gemini HIV Study Results

(Alliance News) - GlaxoSmithKline PLC on Wednesday noted positive results from the Gemini and Tango phase three studies of a dolutegravir plus lamivudine in HIV patients.The results were by

24 Jul 19 17:20

TOP NEWS: GlaxoSmithKline Profit Up In First Half; Guidance Improved

(Alliance News) - GlaxoSmithKline PLC on Wednesday said its profit rose almost 50% in the first half of the year due to strong performances from its Vaccines and Consumer Healthcare also upgraded

24 Jul 19 12:35

LONDON MARKET MIDDAY: Miners Press FTSE Deeper Into Red On Vale News

(Alliance News) - Miners put the FTSE 100 under pressure on Wednesday while the FTSE 250 battled to stay in the green in the face of a 24% slump for luxury car maker Aston large-cap FTSE a

24 Jul 19 11:53

TOP NEWS: GlaxoSmithKline Hires Ex-Astra Finance Boss Symonds As Chair

(Alliance News) - GlaxoSmithKline PLC said Wednesday former AstraZeneca PLC finance chief Jonathan Symonds will replace outgoing Chair Philip Hampton at the FTSE 100-listed drugmaker from the of a

24 Jul 19 10:34

GlaxoSmithKline's ViiV Healthcare Gets Positive Fostemsavir Results

(Alliance News) - GlaxoSmithKline PLC on Monday said its ViiV Healthcare has seen positive results from the phase three Brighte study of investigational fostemsavir in heavily adults with is HIV a

22 Jul 19 17:19

UK Earnings, Trading Statements Calendar - Next 7 Days

Thursday 18 July Scieifitic Digital Imaging Half Year ResultsAudioboomHalf Year Year

17 Jul 19 16:07

Mereo BioPharma Names Richard Francis As New Pharmaceutical Head

(Alliance News) - Mereo BioPharma has appointed Richard Francis as the new head of pharmaceutical development, effective August 1, the biopharmaceutical company said on Tuesday.Francis was

16 Jul 19 14:46

Glaxo Reports Positive Study Results For Cancer Treatment Zejula

(Alliance News) - GlaxoSmithKline on Monday said a study of ovarian cancer treatment Zejula met its primary endpoint of a statistically significant improvement in progression free survival for of

15 Jul 19 08:43

LONDON MARKET PRE-OPEN: Glaxo Gets Positive Results From Zejula Study

(Alliance News) - Stock prices in London are seen opening slightly higher on Monday, tracking gains in Chinese equity markets despite a reported slowdown in economic growth there.In early UK news,

15 Jul 19 07:40

TOP NEWS: GlaxoSmithKline Notes Positive Study Of HIV Two-Drug Regimen

(Alliance News) - GlaxoSmithKline PLC on Wednesday noted that the Tango study of a dolutegravir plus lamivudine two-drug regimen in HIV-1 met its primary endpoint.The phase 3 Tango study a

10 Jul 19 07:57

GSK's ViiV Trials Monthly HIV Treatment In US Clinics

(Alliance News) - GlaxoSmithKline PLC on Monday said ViiV Healthcare has commenced a trial to identify and evaluate approaches to implementing a once-monthly, injectable treatment for HIV into is

8 Jul 19 13:53

Login to your account

Don't have an account? Click here to register.